Pricing Log in Create free account
Friday 6 November 2026 Export TECH’s income statement to Excel — free account

Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025.

Revenue
+1.33%
EPS
+418.2%
Free cash flow
−6.83%
Total debt
−42.2%

Quarter to June 2026, against a year earlier

72.79 0.13 +0.18%
Market cap
$11.4B
P/E
62.2×
Fwd P/E
54.2×
Dividend yield
0.44%
F-score
9/9
Altman Z
15.50
Beneish M
−2.52
Dividend safety
78/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Bio-Techne Corp 10-Q filed May 8, 2025

Fiscal Q3 2025 · Period ended Mar 31, 2025 · Filed · accepted 4:30 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Feb 6, 2025: 1 added · 1 removed · 22 modified; 10 with only figures updated

  1. Modified · RECENT ACQUISITIONS

    A key component of the Company's strategy is to augment internal growth at existing businesses with complementary acquisitions. The Company did not make any acquisitions in the first halfnine months of fiscal 2025.